Table S1, Table S2, Table S3, Table S4 from Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Patient biomarkers/NGS has four categories: (+), (-), N/A, and Gain Supplementary Table 2: Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Supplementary Table 3. Event-free survival of PDXs compared to patient response. Event-free survival of PDXs compared to patient response. Supplementary Table 4. Immunohistochemistry antibodies.